Related Experiment Video

Updated: Sep 27, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The selection of antithrombotic agents in the prevention of recurrent ischemic stroke

Cathy M Helgason1

  • 1University of Illinois at Chicago, 912 South Wood Street, M/C 796, Chicago, IL 60612, USA. helgason@uic.edu

Current Cardiology Reports
|February 14, 2003
PubMed

Insights

Individualized antithrombotic therapy selection, moving beyond group averages, offers targeted prevention for recurrent thrombus and thromboembolism in stroke patients by considering unique patient conditions.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Current antithrombotic therapy selection relies on group-based statistical data in evidence-based medicine.
  • Large randomized trials average patient data, obscuring individual patient initial conditions and context.
  • This group-based approach limits the precise application of antithrombotic agents for preventing recurrent thrombus and thromboembolism.

Purpose of the Study:

  • To introduce a pathologic model for selecting antithrombotic therapy based on individual patient characteristics.
  • To explore alternative mathematical and perception-based models for personalized antithrombotic treatment.
  • To emphasize the importance of initial patient conditions in guiding targeted antithrombotic therapy.

Main Methods:

  • Review of existing group-based statistical interpretation in antithrombotic therapy selection.
  • Proposal of a pathologic model for antithrombotic agent choice in stroke patients.
  • Discussion of alternative mathematical models and perception-based science focusing on individual patient data.
  • Emphasis on maintaining the connection between the model and the patient's unique context.

Main Results:

  • Group-based data interpretation in evidence-based medicine loses individual patient initial conditions.
  • A pathologic model exists for selecting antithrombotic agents for recurrent thrombus and thromboembolism prevention.
  • Alternative models can capture causal mechanisms within the patient's body by respecting initial conditions.
  • Individualized choices ensure thrombus-type specific targeted therapy.

Conclusions:

  • Personalized antithrombotic therapy selection is crucial for effective prevention of recurrent thrombus and thromboembolism.
  • Moving beyond group-based statistics to individualized, context-aware models improves therapeutic targeting.
  • Future research should test models that integrate individual patient data for optimized antithrombotic treatment strategies.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.